MA37569B1 - Molécules d'anticorps anti-gcc et leur utilisation en vue de tester la sensibilité à une thérapie ciblée sur la gcc - Google Patents

Molécules d'anticorps anti-gcc et leur utilisation en vue de tester la sensibilité à une thérapie ciblée sur la gcc

Info

Publication number
MA37569B1
MA37569B1 MA37569A MA37569A MA37569B1 MA 37569 B1 MA37569 B1 MA 37569B1 MA 37569 A MA37569 A MA 37569A MA 37569 A MA37569 A MA 37569A MA 37569 B1 MA37569 B1 MA 37569B1
Authority
MA
Morocco
Prior art keywords
gcc
antibody molecules
relates
methods
immunoconjugates
Prior art date
Application number
MA37569A
Other languages
English (en)
Inventor
Helen Frank
Alice Mcdonald
Theresa O'keefe
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of MA37569B1 publication Critical patent/MA37569B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/988—Lyases (4.), e.g. aldolases, heparinase, enolases, fumarase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)

Abstract

La présente invention concerne des anticorps et des fragments liant les antigènes d'anticorps liant la gcc. L'invention concerne également des méthodes de diagnostic permettant d'identifier des patients qui devraient recevoir une thérapie ciblée sur la gcc utilisant les anticorps anti-gcc de la présente invention. Les molécules d'anticorps anti-gcc peuvent être utilisées en tant que molécules d'anticorps nus et en tant que composants d'immunoconjugués. En conséquence, selon un autre aspect, l'invention concerne des immunoconjugués comprenant une molécule d'anticorps anti-gcc selon la présente invention et un agent thérapeutique ou un marqueur. L'invention concerne également des méthodes d'utilisation des molécules d'anticorps anti-gcc et des immunoconjugués décrits ici, par exemple en vue de la détection de la gcc et de cellules ou de tissus exprimant la gcc. Lesdites méthodes peuvent être utilisées, entre autres, en vue du diagnostic, du pronostic, de l'imagerie ou de la détermination des stades d'une maladie évolutive à médiation par la gcc. En conséquence, selon certains aspects, l'invention concerne des méthodes d'identification d'un sujet devant faire l'objet d'un traitement par une thérapie ciblée sur la gcc, par exemple une thérapie à base d'anticorps anti-gcc, faisant notamment appel à un immunoconjugué comprenant un anticorps anti-gcc conjugué à un agent thérapeutique.
MA37569A 2012-04-27 2013-04-27 Molécules d'anticorps anti-gcc et leur utilisation en vue de tester la sensibilité à une thérapie ciblée sur la gcc MA37569B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261639376P 2012-04-27 2012-04-27
PCT/US2013/038542 WO2013163633A1 (fr) 2012-04-27 2013-04-27 Molécules d'anticorps anti-gcc et leur utilisation en vue de tester la sensibilité à une thérapie ciblée sur la gcc

Publications (1)

Publication Number Publication Date
MA37569B1 true MA37569B1 (fr) 2020-08-31

Family

ID=49477498

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37569A MA37569B1 (fr) 2012-04-27 2013-04-27 Molécules d'anticorps anti-gcc et leur utilisation en vue de tester la sensibilité à une thérapie ciblée sur la gcc

Country Status (41)

Country Link
US (3) US9000129B2 (fr)
EP (1) EP2841575B1 (fr)
JP (2) JP6472746B2 (fr)
KR (1) KR102046435B1 (fr)
CN (1) CN104395470B (fr)
AR (1) AR090884A1 (fr)
AU (1) AU2013251312B2 (fr)
CA (1) CA2871614C (fr)
CL (1) CL2014002911A1 (fr)
CO (1) CO7280144A2 (fr)
CR (1) CR20140497A (fr)
CY (1) CY1122557T1 (fr)
DK (1) DK2841575T3 (fr)
DO (1) DOP2014000242A (fr)
EA (1) EA034689B1 (fr)
EC (1) ECSP14028523A (fr)
ES (1) ES2749181T3 (fr)
GE (1) GEP201706737B (fr)
HK (1) HK1208049A1 (fr)
HR (1) HRP20191690T1 (fr)
HU (1) HUE046404T2 (fr)
IL (1) IL235307B (fr)
LT (1) LT2841575T (fr)
MA (1) MA37569B1 (fr)
ME (1) ME03560B (fr)
MX (1) MX362020B (fr)
MY (1) MY188442A (fr)
NZ (1) NZ701601A (fr)
PE (1) PE20142322A1 (fr)
PH (1) PH12014502399A1 (fr)
PL (1) PL2841575T3 (fr)
PT (1) PT2841575T (fr)
RS (1) RS59370B1 (fr)
SA (1) SA113340502B1 (fr)
SG (1) SG11201406855TA (fr)
SI (1) SI2841575T1 (fr)
TN (1) TN2014000454A1 (fr)
TW (1) TWI631137B (fr)
UA (1) UA117910C2 (fr)
WO (1) WO2013163633A1 (fr)
ZA (1) ZA201407723B (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG179567A1 (en) 2009-10-23 2012-05-30 Millennium Pharm Inc Anti-gcc antibody molecules and related compositions and methods
EP3060580B1 (fr) * 2013-10-21 2021-03-31 Centre For Drug Research And Development Anticorps anti-podocalyxine et leurs méthodes d'utilisation
US10351897B2 (en) 2014-02-14 2019-07-16 Bioventures, Llc Acetaminophen adducts and methods of use thereof
JP6785239B2 (ja) 2014-12-03 2020-11-18 バイオベンチャーズ・リミテッド・ライアビリティ・カンパニーＢｉｏＶｅｎｔｕｒｅｓ， ＬＬＣ 抗アセトアミノフェン抗体及びアセトアミノフェンタンパク質付加物
AU2016333175B2 (en) 2015-10-01 2023-08-24 The Centre For Drug Research And Development Anti-podocalyxin antibodies and methods of using the same
CN110268108B (zh) 2016-12-12 2022-09-06 埃克切拉生物科学公司 用于使用微毛细管阵列进行筛选的方法和系统
KR102080887B1 (ko) * 2017-11-07 2020-02-24 고려대학교 산학협력단 Gcc2 유전자 또는 단백질을 과발현하는 엑소좀 기반 폐암 진단 또는 예후 예측용 마커 조성물
JP7197584B2 (ja) * 2017-12-06 2022-12-27 ベンタナ メディカル システムズ， インコーポレイテッド デジタル病理学分析結果の格納および読み出し方法
US11568657B2 (en) 2017-12-06 2023-01-31 Ventana Medical Systems, Inc. Method of storing and retrieving digital pathology analysis results
US20210330736A1 (en) * 2018-09-05 2021-10-28 Universiteit Van Amsterdam Use of a pde11 or pde2 inhibitor for the treatment of parkinson's disease
WO2021205325A1 (fr) * 2020-04-08 2021-10-14 Pfizer Inc. Anticorps anti-gucy2c et leurs utilisations
CA3176119A1 (fr) * 2020-06-02 2021-12-09 Teijin Pharma Limited Anticorps humanise de recepteur anti-igf-1
IL303610A (en) * 2020-12-17 2023-08-01 Parasol Biotech Ltd GUCY2C binding molecules and their uses
WO2024067762A1 (fr) * 2022-09-28 2024-04-04 Nanjing Legend Biotech Co., Ltd. Anticorps et récepteurs antigéniques chimériques ciblant gcc et leurs procédés d'utilisation
US20240165257A1 (en) 2022-11-01 2024-05-23 Heidelberg Pharma Research Gmbh Anti-gucy2c antibody and uses thereof
CN116535514B (zh) * 2023-06-15 2024-02-02 上海斯丹赛生物技术有限公司 抗鸟苷酸环化酶c抗体及其在癌症治疗中的应用

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5237051A (en) 1990-12-06 1993-08-17 Vanderbilt University Purified enterotoxin receptor protein
US7097839B1 (en) 1993-10-26 2006-08-29 Thomas Jefferson University ST receptor binding compounds and methods of using the same
US5601990A (en) 1994-09-13 1997-02-11 Thomas Jefferson University Methods of diagnosing colorectal tumors and metastasis thereof
US5518888A (en) 1993-10-26 1996-05-21 Thomas Jefferson University ST receptor binding compounds and methods of using the same
US6060037A (en) 1993-10-26 2000-05-09 Thomas Jefferson University Compositions that specifically bind to colorectal cancer cells and methods of using the same
US5879656A (en) 1993-10-26 1999-03-09 Thomas Jefferson University Methods of treating metastatic colorectal cancer with ST receptor binding compounds
US6455251B1 (en) 1994-09-13 2002-09-24 Thomas Jefferson University Methods of and kits and compositions for diagnosing colorectal tumors and metastasis thereof
WO1997042506A1 (fr) 1996-05-03 1997-11-13 Thomas Jefferson University Procedes et trousses de diagnostic et compositions permettant de diagnostiquer des tumeurs colorectales et leurs metastases
CA2254082C (fr) 1996-05-03 2012-09-11 Thomas Jefferson University Vaccin contre le cancer recto-colique metastatique
US6120995A (en) 1997-08-07 2000-09-19 Thomas Jefferson University Compositions that specifically bind to colorectal cancer cells and methods of using the same
US6696550B2 (en) 1998-07-23 2004-02-24 Millennium Pharmaceuticals, Inc. Humanized anti-CCR2 antibodies and methods of use therefor
US8092514B1 (en) 1998-11-16 2012-01-10 Boston Scientific Scimed, Inc. Stretchable anti-buckling coiled-sheet stent
US20040031072A1 (en) 1999-05-06 2004-02-12 La Rosa Thomas J. Soy nucleic acid molecules and other molecules associated with transcription plants and uses thereof for plant improvement
ES2346637T3 (es) 2000-03-27 2010-10-19 Thomas Jefferson University Composiciones y metodos para identificar y marcar celulas cancerosas originadas en el tubo digestivo.
TWI255272B (en) 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
DK1377314T3 (da) 2001-01-26 2011-12-12 Inhibitex Inc Monoklonale antistoffer mod CLFA-proteinet og fremgangsmåder til anvendelse i behandling eller forebyggelse af infektioner
DK1379224T4 (da) 2001-03-29 2013-12-02 Synergy Pharmaceuticals Inc Guanylat-cyklase-receptoragonister til behandling af vævsbetændelse og karcinogenese
NZ529494A (en) 2001-04-13 2005-08-26 Biogen Idec Inc Antibodies to VLA-1
DE60220719T2 (de) 2001-12-28 2008-03-06 Amgen Fremont Inc. Antikörper gegen das muc18-antigen
US20040110933A1 (en) 2002-09-13 2004-06-10 Dyax Corporation CD44-binding ligands
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
US7371727B2 (en) 2003-01-28 2008-05-13 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7304036B2 (en) 2003-01-28 2007-12-04 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
WO2004071436A2 (fr) 2003-02-10 2004-08-26 Thomas Jefferson University Utilisation de ligands gcc
US20090005257A1 (en) 2003-05-14 2009-01-01 Jespers Laurent S Process for Recovering Polypeptides that Unfold Reversibly from a Polypeptide Repertoire
US7871610B2 (en) 2003-08-12 2011-01-18 Dyax Corp. Antibodies to Tie1 ectodomain
EP1781339B1 (fr) 2004-06-25 2013-12-25 Thomas Jefferson University Ligands de la Guanylyle cyclase C
EP1838733B1 (fr) 2004-12-21 2011-08-24 Medimmune Limited Anticorps diriges contre l'angiopoietine 2 et leurs utilisations
AR056857A1 (es) 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
CN101772513B (zh) 2007-06-04 2013-11-13 协同医药品公司 有效用于胃肠功能紊乱、炎症、癌症和其他疾病治疗的鸟苷酸环化酶激动剂
CA2696011A1 (fr) * 2007-08-10 2009-02-19 Centocor Ortho Biotech Inc. Fragments de clivage d'immunoglobulines utilises comme indicateurs de maladies, et compositions permettant de detecter et de fixer ces fragments
MY153781A (en) 2007-08-10 2015-03-13 Regeneron Pharma High affinity human antibodies to human nerve growth factor
PL2220492T3 (pl) * 2007-11-30 2012-01-31 Genentech Inc Polimorfizmy VEGF oraz terapia antyangiogenna
US20110195415A1 (en) 2008-05-13 2011-08-11 Thomas Jefferson University Guanylyl cyclase c qrt-pcr
ES2559840T3 (es) 2008-06-04 2016-02-16 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
EP3241839B1 (fr) 2008-07-16 2019-09-04 Bausch Health Ireland Limited Agonistes de guanylate cyclase utiles pour le traitement de troubles gastro-intestinaux, inflammatoires, cancéreux et autres
EP2370098A4 (fr) * 2008-12-03 2013-07-17 Morphosys Ag Anticorps contre les récepteurs de guanylyle cyclase
US9364477B2 (en) * 2009-02-12 2016-06-14 Cell Signaling Technology, Inc. Mutant ROS expression in human cancer
WO2010096929A1 (fr) 2009-02-25 2010-09-02 Diagnocure Inc. Procédé de détection de métastase d'un cancer du tractus gastro-intestinal
JPWO2010104035A1 (ja) * 2009-03-12 2012-09-13 学校法人近畿大学 非小細胞肺癌に対する化学療法の治療効果予測方法
CA2801729A1 (fr) 2009-06-15 2010-12-23 Thomas Jefferson University Compositions et procedes d'activation de la guanylyl cyclase c
EP3444333A1 (fr) 2009-10-22 2019-02-20 Thomas Jefferson University Compositions anticancéreuses a base de cellules et leurs procédés de fabrication et d'utilisation
SG179567A1 (en) * 2009-10-23 2012-05-30 Millennium Pharm Inc Anti-gcc antibody molecules and related compositions and methods
WO2011150454A1 (fr) * 2010-06-01 2011-12-08 Monash University Anticorps dirigés contre le récepteur tyrosine kinase c-met
JP2013539460A (ja) * 2010-08-13 2013-10-24 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ベバシズマブ併用療法のためのバイオマーカーとしてのニューロピリン
US20150086481A1 (en) 2011-07-28 2015-03-26 Memorial Sloan-Kettering Cancer Center Diagnosis and treatment of parkinson's disease
US9156915B2 (en) 2012-04-26 2015-10-13 Thomas Jefferson University Anti-GCC antibody molecules
CN105142664A (zh) * 2013-02-28 2015-12-09 米伦纽姆医药公司 投予抗gcc抗体-药物结合物和dna破坏剂来治疗癌症

Also Published As

Publication number Publication date
JP6472746B2 (ja) 2019-02-20
MX362020B (es) 2019-01-04
TW201348258A (zh) 2013-12-01
AR090884A1 (es) 2014-12-10
MX2014013081A (es) 2015-01-12
KR102046435B1 (ko) 2019-11-19
US9000129B2 (en) 2015-04-07
PL2841575T3 (pl) 2020-01-31
UA117910C2 (uk) 2018-10-25
CL2014002911A1 (es) 2015-01-30
ME03560B (fr) 2020-07-20
PE20142322A1 (es) 2015-01-25
RS59370B1 (sr) 2019-11-29
SI2841575T1 (sl) 2019-11-29
ECSP14028523A (es) 2015-09-30
WO2013163633A1 (fr) 2013-10-31
EA034689B1 (ru) 2020-03-06
TWI631137B (zh) 2018-08-01
US20130287783A1 (en) 2013-10-31
TN2014000454A1 (en) 2016-03-30
MY188442A (en) 2021-12-09
KR20150004882A (ko) 2015-01-13
HK1208049A1 (en) 2016-02-19
CO7280144A2 (es) 2015-05-29
ZA201407723B (en) 2019-01-30
DOP2014000242A (es) 2014-11-30
SA113340502B1 (ar) 2015-09-17
HUE046404T2 (hu) 2020-02-28
EA201491977A1 (ru) 2015-04-30
HRP20191690T1 (hr) 2019-12-27
EP2841575A1 (fr) 2015-03-04
CN104395470A (zh) 2015-03-04
JP2015516985A (ja) 2015-06-18
EP2841575A4 (fr) 2016-06-15
GEP201706737B (en) 2017-09-25
CN104395470B (zh) 2018-02-06
US9273146B1 (en) 2016-03-01
CA2871614A1 (fr) 2013-10-31
US20160130344A1 (en) 2016-05-12
CR20140497A (es) 2015-02-10
EP2841575B1 (fr) 2019-06-26
CY1122557T1 (el) 2021-01-27
AU2013251312A1 (en) 2014-10-30
DK2841575T3 (da) 2019-09-23
SG11201406855TA (en) 2014-11-27
IL235307A0 (en) 2014-12-31
PT2841575T (pt) 2019-10-11
AU2013251312B2 (en) 2018-03-22
PH12014502399B1 (en) 2014-12-22
JP6517267B2 (ja) 2019-05-22
NZ701601A (en) 2016-09-30
PH12014502399A1 (en) 2014-12-22
BR112014026742A2 (pt) 2017-07-11
JP2017131245A (ja) 2017-08-03
CA2871614C (fr) 2021-08-31
IL235307B (en) 2019-07-31
ES2749181T3 (es) 2020-03-19
LT2841575T (lt) 2019-10-10

Similar Documents

Publication Publication Date Title
MA37569B1 (fr) Molécules d'anticorps anti-gcc et leur utilisation en vue de tester la sensibilité à une thérapie ciblée sur la gcc
Lim et al. Therapeutic effects of human umbilical cord blood-derived mesenchymal stem cells after intrathecal administration by lumbar puncture in a rat model of cerebral ischemia
MA44101B1 (fr) Peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer du sein et d'autres cancers
MA43090A1 (fr) Peptides, combinaisons de peptides et médicaments basés sur les cellules pour l'immunothérapie contre le cancer de la vessie urinaire et d'autres cancers
MA42381A (fr) Nouveaux peptides et nouvelle combinaison de peptides à utiliser dans l'immunothérapie du cancer de l' oesophage et d'autres cancers
MA46647A1 (fr) Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie du cancer du pancréas et d'autres cancers
MA43490A1 (fr) Nouveaux peptides et combinaison de peptides destinés à être utilisés dans l'immunothérapie contre divers cancers
MA43458A1 (fr) Nouveaux peptides, combinaisons de peptides et supports pour utilisation dans le traitementimmunothérapeutique de divers cancers
MA46022B1 (fr) Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de la prostate et d'autres cancers
MA46504A1 (fr) Nouveaux épitopes de cellules et nouvelle combinaison d'épitopes de cellules destinés à être utilisés dans l'immunothérapie du myélome et d'autres cancers
CO6351751A2 (es) Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
MA41520B2 (fr) Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de l'ovaire et d'autres cancers
MA43435B1 (fr) Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie contre diverses tumeurs (seq id 25 - mrax5-003)
MA49158B1 (fr) Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie contre le carcinome hépatocellulaire (hcc) et d'autres cancers
AR070168A1 (es) Anticuerpos anti-cd79b e inmunoconjugados y metodos de uso de los mismos
WO2008103645A8 (fr) Antigènes spécifiques du cancer de la prostate et du mélanome
CR10143A (es) Antígenos de ácido des-n-acetil-siálico, anticuerpos para los mismos y métodos de uso en la terapia del cáncer
WO2015014903A3 (fr) Instruments de diagnostic pour la maladie d'alzheimer
ECSP15028696A (es) Anticuerpos anti-lamp1 y conjugados anticuerpo fármaco, y usos de éstos
Libner et al. Antibodies to the RNA binding protein heterogeneous nuclear ribonucleoprotein A1 contribute to neuronal cell loss in an animal model of multiple sclerosis
Kim et al. In Situ Detection of HY-Specific T Cells in Acute Graft-versus-Host Disease–Affected Male Skin after Sex-Mismatched Stem Cell Transplantation
Arrieta et al. Ultrasound-mediated delivery of doxorubicin to the brain results in immune modulation and improved responses to PD-1 blockade in gliomas
MA34291B1 (fr) Compositions et méthodes de diagnostic et de traitement d'une tumeur
Ermaya et al. Correlation between Endoscopy Finding with Clinical Manifestations of Recurrent Abdominal Pain and Helicobacter pylori Infection
Ravenni et al. VALIDATION OF NEUROTENSIN TETRA-BRANCHED PEPTIDES AS TUMOR TARGETING AGENTS IN PANCREAS, COLON AND BLADDER CARCINOMA